Jacobs Engineering Group Inc. (NYSE:JEC) has been selected by Aerie Pharmaceuticals Inc. (NASDAQ:AERI) to provide engineering, procurement and construction management services (EPCM) for Aerie's first pharmaceutical manufacturing facility, located in the Industrial Development Authority (IDA)'s advanced technology building in Athlone, Republic of Ireland. Under the terms of the contract, Jacobs will outfit Aerie's manufacturing facility for commercial processing of sterile ophthalmic solutions. The ophthalmic solutions will be compounded, sterile filtered and filled aseptically. Aerie's lead product candidates are new chemical entities focused on treating patients with glaucoma or ocular hypertension. "Leveraging our extensive experience in EPCM for fill-finish facilities, we'll work alongside Aerie to support their important goal of developing first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye," said Jacobs Life Sciences, Consumer Goods and Manufacturing Senior Vice President and General Manager Ken Gilmartin. "Key to Aerie's selection of Jacobs to support the design and construction of our first manufacturing plant was their proven capability and track record of delivering sterile manufacturing facilities," said Barry Ivin, Site Director, Aerie Athlone. Jacobs has designed more than 30 fill-finish facilities across the world over the past 10 years. Jacobs is one of the world's largest and most diverse providers of full-spectrum technical, professional and construction services for industrial, commercial and government organizations globally. The company employs over 54,000 people and operates in more than 25 countries around the world. For more information, visit www.jacobs.com. Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management's current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our Form 10-K for the year ended September 30, 2016, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.